Jeffrey W. Albers, a director at Blueprint Medicines Corp (NASDAQ:BPMC), recently executed significant stock transactions, according to a filing with the Securities and Exchange Commission. The company, currently trading at $115.63 and valued at $7.34 billion, has seen its stock surge 32.57% year-to-date and is trading near its 52-week high of $121.90. On January 21, Albers sold a total of 15,161 shares of Blueprint Medicines' common stock. The shares were sold at prices ranging from $109.11 to $110.61 per share, generating a total transaction value of approximately $1.66 million.
In addition to the sales, Albers exercised stock options to acquire 10,000 shares at a price of $36.05 each, a transaction valued at $360,500. Following these transactions, Albers holds 152,396 shares of Blueprint Medicines directly.
These transactions were conducted under a trading plan adopted in May 2024, in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
In other recent news, Blueprint Medicines Corporation experienced a surge in shares following an outlined growth strategy for 2025 and positive trial data for its new treatment, BLU-808. The company updated its peak revenue estimate for its systemic mastocytosis (SM) franchise to $4 billion, driven by the successful launch of AYVAKIT and revised prevalence estimates for SM. Results from a Phase 1 healthy volunteer study of BLU-808 showed promising results, supporting its potential as a best-in-class treatment for a range of mast cell-driven diseases.
Analysts from Stifel and Needham have maintained a Buy rating for Blueprint Medicines, while JPMorgan initiated coverage with an Overweight rating. These ratings were influenced by the company's strategic approach and financial position, as well as the potential of its BLU-808 drug and the robust sales of AYVAKIT.
Blueprint Medicines reported significant revenue growth, primarily driven by AYVAKIT sales, leading to an adjustment of its revenue expectations for the year to between $475 million and $480 million. The company is also focusing on advancing its pipeline, including the initiation of the Phase 3 HARBOR trial of elenestinib for indolent systemic mastocytosis and investment in CDK targeted protein degraders for breast cancer and other solid tumors. These are recent developments that continue to shape the trajectory of Blueprint Medicines Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.